Recent developments for Soleno Therapeutics include the appointment of Jennifer Fulk as Chief Financial Officer in early 2026 and the announcement of a $2.9 billion all-cash acquisition agreement by Neurocrine Biosciences in April 2026. These events have been accompanied by notable stock price movements and increased market attention.

• Soleno Therapeutics appointed Jennifer Fulk as Chief Financial Officer effective March 2026, supporting financial leadership continuity [N3].
• In April 2026, Soleno entered into a definitive merger agreement to be acquired by Neurocrine Biosciences for $53.00 per share in an all-cash transaction valued at approximately $2.9 billion [N1].
• Following the acquisition announcement, Soleno's stock rallied significantly, with a 56.4% increase reported in early April 2026 [N2].
• The acquisition agreement includes customary conditions such as tender offer thresholds, regulatory approvals, and treatment of outstanding options and warrants [N1].

Soleno Therapeutics has demonstrated operational progress with profitability in 2025 and a strong liquidity position, enabling continued investment in its rare disease product portfolio. The company's experienced management team and board provide strategic and operational expertise in biopharmaceutical development and commercialization. The recent acquisition agreement with Neurocrine Biosciences at a premium cash price reflects the value of Soleno's assets and pipeline. The commercial presence of VYKATTM XR and ongoing clinical and regulatory activities support potential for sustained revenue generation. The company's focus on rare diseases may benefit from regulatory incentives and market exclusivity, enhancing its commercial prospects.

Soleno Therapeutics faces risks typical of biopharmaceutical companies, including the uncertainty of clinical trial success, regulatory approval processes, and market uptake of its products. The integration risks associated with the pending acquisition by Neurocrine Biosciences may disrupt business operations or delay strategic initiatives. The company's financial performance and valuation are subject to market and industry volatility. Additionally, the competitive landscape in rare disease therapeutics and potential challenges in commercialization could impact future revenue streams. The company's reliance on a limited product portfolio and the inherent risks of drug development present ongoing operational and financial uncertainties.

Soleno Therapeutics operates in the specialized niche of rare disease therapeutics, which often involves high barriers to entry due to complex clinical development, regulatory hurdles, and the need for specialized commercialization expertise. The company's leadership and board bring extensive experience in rare disease drug development and commercialization, which supports its competitive positioning. Its commercial product, VYKATTM XR, addresses a specific rare disease indication, potentially benefiting from orphan drug designations and market exclusivity. The company's strong liquidity position provides financial flexibility to support ongoing development and commercialization efforts. However, the biopharmaceutical industry is characterized by significant risks including clinical trial outcomes, regulatory approvals, and market acceptance, which can impact the sustainability of competitive advantages.

• Acquisition and Integration Risk: The pending acquisition by Neurocrine Biosciences involves risks related to regulatory approvals, integration challenges, and realization of anticipated benefits, which may affect business continuity and financial performance.
• Clinical and Regulatory Risk: Soleno's product development is subject to the uncertainties of clinical trial outcomes and regulatory approval processes, which can delay or prevent product commercialization.
• Market Uptake Risk: The degree and pace of market adoption of Soleno's commercial product VYKATTM XR and other pipeline products are uncertain and may impact revenue generation.
• Financial and Operational Risk: Despite recent profitability, the company operates in a capital-intensive industry with risks related to funding, cost management, and competitive pressures.

• Soleno Therapeutics, Inc. is a Delaware corporation headquartered in Redwood City, California [S1].
• The company is publicly traded on NASDAQ under the ticker SLNO [S1].
• As of April 29, 2026, Soleno had 52,120,147 shares of common stock outstanding [S1].
• The company is classified as a large accelerated filer and is not an emerging growth company [S1].
• Soleno's board of directors consists of six members with diverse experience in biopharmaceuticals and related industries, including CEO and Chairman Dr. Anish Bhatnagar [S1].
• Key executive officers include CEO Anish Bhatnagar, CFO Jennifer Fulk (appointed March 2026), Chief Commercial Officer Meredith Manning, Chief Development Officer Manher Joshi, Chief Business Officer Kevin Norrett, and senior vice presidents in regulatory affairs and clinical operations [S1].
• The company reported net income of $20.89 million and basic earnings per share of $0.40 for the fiscal year ended December 31, 2025 [S1].
• Cash and cash equivalents were $70.1 million, with short-term investments of $235.4 million, totaling current assets of $355.8 million against current liabilities of $61.4 million as of December 31, 2025, resulting in a current ratio of 5.8 and a cash ratio of 4.98 [S1].
• Soleno has a commercial product named VYKATTM XR (diazoxide choline) with market uptake being a key business consideration [S2].
• On April 5, 2026, Soleno entered into a merger agreement with Neurocrine Biosciences, Inc. for an all-cash acquisition at $53.00 per share, subject to tender offer conditions and regulatory approvals [S2].
• The merger agreement includes provisions for option and warrant treatment, customary representations, warranties, and covenants, and is not subject to financing conditions [S2].
• The company has a history of clinical development and regulatory activities, including involvement in rare disease therapies and orphan drug designations [S1].
• Recent news highlights include the appointment of Jennifer Fulk as CFO in early 2026 and a significant stock rally following the announcement of the acquisition by Neurocrine Biosciences [N3][N2][N1].
• The company has demonstrated profitability with $66 million in revenue reported in prior years and a net income in 2025, indicating operational progress [N4][S1].
• Soleno's board and management have extensive experience in biopharmaceutical commercialization, clinical development, and finance, supporting strategic execution [S1].